NCT01320020 2013-07-02A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer PatientsNeovii BiotechPhase 1 Terminated16 enrolled
NCT00189345 2006-11-08Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer PatientsAGO Study GroupPhase 2 Completed44 enrolled